Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Aldosterone"

Keywords

Publication year

"Aldosterone"

Original Articles
Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
Hyun Ju Lee, Jasung Rho, Shao Ran Gui, Mi Kyung Kim, Yu Kyoung Lee, Yeon Sook Lee, Jeong Eun Kim, Euna Cho, Mong Cho, Tae-Ho Hwang
Korean J Hepatol 2011;17(3):213-219.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.213
Background/Aims

JX-594 is an oncolytic virus derived from the Wyeth vaccinia strain that causes replication-dependent cytolysis and antitumor immunity. Starting with a cross-examination of clinical-trial samples from advanced hepatocellular carcinoma patients having high levels of aldosterone and virus amplification in JX-594 treatment, we investigated the association between virus amplification and aldosterone in human cancer cell lines.

Methods

Cell proliferation was determined by a cell-counting-kit-based colorimetric assay, and vaccinia virus quantitation was performed by quantitative polymerase chain reaction (qPCR) and a viral plaque assay. Also, the intracellular pH was measured using a pH-sensitive dye.

Results

Simultaneous treatment with JX-594 and aldosterone significantly increased viral replication in A2780, PC-3, and HepG2 cell lines, but not in U2OS cell lines. Furthermore, the aldosterone treatment time altered the JX-594 replication according to the cell line. The JX-594 replication peaked after 48 and 24 hours of treatment in PC-3 and HepG2 cells, respectively. qPCR showed that JX-594 entry across the plasma membrane was increased, however, the changes are not significant by the treatment. This was inhibited by treatment with spironolactone (an aldosterone-receptor inhibitor). JX-594 entry was significantly decreased by treatment with EIPA [5-(N-ethyl-N-isopropyl)amiloride; a Na+/H+-exchange inhibitor], but aldosterone significantly restored JX-594 entry even in the presence of EIPA. Intracellular alkalization was observed after aldosterone treatment but was acidified by EIPA treatment.

Conclusions

Aldosterone stimulates JX-594 amplification via increased virus entry by affecting the H+ gradient.

Citations

Citations to this article as recorded by  Crossref logo
  • Research progress and development potential of oncolytic vaccinia virus
    Xinyu Zhang, Jiangshan He, Yiming Shao
    Chinese Medical Journal.2025; 138(7): 777.     CrossRef
  • Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
    Nabil V Sayour, Ágnes M Paál, Pietro Ameri, Wouter C Meijers, Giorgio Minotti, Ioanna Andreadou, Antonella Lombardo, Massimiliano Camilli, Heinz Drexel, Erik Lerkevang Grove, Gheorghe Andrei Dan, Andreea Ivanescu, Anne Grete Semb, Gianluigi Savarese, Dobr
    European Heart Journal.2024; 45(14): 1224.     CrossRef
  • Recent progress in combination therapy of oncolytic vaccinia virus
    Seyedeh Nasim Mirbahari, Miles Da Silva, Abril Ixchel Muñoz Zúñiga, Nika Kooshki Zamani, Gabriel St-Laurent, Mehdi Totonchi, Taha Azad
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • 9,644 View
  • 45 Download
  • Crossref
The Usefulness of Monitoring of Transtubular Potassium Gradient and Spot Urine [Na] / [K] Ratio in the Management of Cirrhotic Ascites
Young Seok Lim,Hyo Suk Lee,Jung Hwan Yoon,Jin Suk Han,Chung Yong Kim
Korean J Hepatol 2000;6(1):12-23.
Background/Aims
: Transtubular potassium gradient(TTKG) is known as the most accurate indicator of aldosterone activity. TTKG may be used to monitor the effectiveness of aldosterone antagonist which is prescribed generally for the management of cirrhotic ascites. Spot urine [Na]/[K] ratio may also be used for the same purpose. Methods: After measuring TTKG, spot urine [Na]/[K] ratio, and plasma aldosterone concentration in each of the 23 patients all who had cirrhotic ascites, 100 mg of spiron- olactone was prescribed to be taken daily for 5 days. When no diuretic response occurred and TTKG was more than 3.5 at the end of 5 days, the dose of spironolactone was increased by 100 mg/day at the interval of 5 days until TTKG decreased to below 3.5. Furosemide was added to the non-responders if their TTKG had dropped to below 3.5. Results : Basal plasma concentration of aldosterone was higher than upper normal limit in 13(57%) patients, and correlated with TTKG significantly(r=0.60, p=0.002). TTKG was calculated to be 3.5±0.67 when assuming the aldosterone activity has been completely blocked. Spot urine [Na]/[K] ratio had significant negative correlation with TTKG before and after the administration of spironolactone. In most patients, diuretic response appeared with the fall of TTKG (especially below 3.5) and with the rise of spot urine [Na]/[K] ratio. In patients who did not respond to a low dose spironolactone, further treatment plan (to increase dose of spironolactone or to add furosemide) was guided by TTKG, and all were successful. Conclusions : TTKG and spot urine [Na]/[K] ratio are good indicators of aldosterone activity, and might be used as useful guidelines in the diuretic management of cirrhotic ascites.(Korean J Hepatol 2000;6:12-23)
  • 3,832 View
  • 33 Download